Lead candidate pacritinib, oral kinase inhibitor w specificity for JAK2, FLT3, IRAK1, and CSF1R in Ph 2 for treatment of myelofibrosis. Upcoming catalysts: CHMP opinion Q1'19, complete enrollment in pacritinib PAC203 Ph 2 study YE 2018.
3101 Western Ave
Seattle, WA 98121
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by